



## SARS-CoV-2 Spike-Based Vaccines

Guest Editors:

**Dr. Umesh Kalathiya**

**Dr. Monikaben Padariya**

**Dr. Peter Maple**

Deadline for manuscript  
submissions:  
**closed (31 August 2023)**

### Message from the Guest Editors

Structurally, SARS-CoV-2 is a nanostructural system consisting of nuclear material surrounded by coat proteins, including a spike (S) glycoprotein. The S protein is most crucial in ACE2 host-cell receptor binding, and hence, it is a main target of the immune system. Though the mortality caused by these  $\beta$ -CoV is substantial, a promising strategy and long-term solution to treat patients infected with the virus is still required. One effective method is to design innovative strategies to develop preventative vaccines considering proteins from the SARS-CoV-2 coronavirus itself. These self-derived vaccines can have several significant impacts on understanding  $\beta$ -CoV; they can induce immune responses, a critical component for vaccinology, and can trigger the production of an antibody repertoire. Despite the significant threat that COVID-19 variants pose to current vaccines, these mutations in the S protein can guide novel current/future key vaccines strategies. This Special Issue aims to gather research (reviews, short reports, hypotheses, research articles, etc.) that addresses all aspects of spike-based vaccine development and the implications of variants.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)